ANALIZE MEDICALE DE LABORATOR
Aici gasiti analizele medicale grupate pe categorii precum si detalii generale si specifice pentru categoriile respective.
Selectati o categorie din lista de mai jos:
Solutie antistress!
Construieste poduri :)
Prinde pisica neagra :)
Glycemion, Inc. To Market BIOSAFE's First FDA Approved Consumer Diabetes Risk Assessment Available In The United States
BIOSAFE Medical
Technologies, Inc. has announced the development of the first consumer test
to evaluate diabetes risk. The Diabetes Risk Assessment test will be
marketed exclusively in the United States by Glycemion, Inc. The BIOSAFE
Diabetes Risk Assessment is a two-part process comprised of an immediate
fasting glucose reading and a mail-in laboratory analysis for hemoglobin
A1c, a blood glucose marker for the previous ninety-day period. Samples for
both tests can be either professionally collected or self-collected through
the use of a simple finger-nick collection kit. Taken in combination, these
two results become a reliable indicator of diabetes or a pre diabetes
condition.
Type 2 diabetes (non-insulin dependent diabetes) affects more than 20
million Americans and is the most common form of the disease. However,
because diabetes exhibits few if any symptoms until its advanced stages,
millions more are in danger of contracting the disease and are unaware of
it. When blood glucose (sugar) levels are higher than normal, but not yet
high enough to be classified as diabetes, a condition known as pre-diabetes
exists. If discovered early, a person with pre-diabetes can avoid the
disease through education, diet, exercise, and appropriately prescribed
medications.
"Diabetes is a debilitating, crippling, and life-shortening disease
whose most serious complications can be prevented with early detection. The
BIOSAFE Diabetes Risk Assessment is a common-sense approach to early
detection of a potentially dangerous condition," said Jack Maggiore, PhD,
president of BIOSAFE Laboratories, Inc. "Despite decades of medical
advances for the treatment of diabetes, millions of people remain
unknowingly undiagnosed and at risk for the disease. By making this quick,
convenient and inexpensive kit available to consumers, we are confident
that those who are identified as being in a pre-diabetic state will work
with their physicians to implement dietary and healthy lifestyle changes to
avoid the onset of diabetes and its catastrophic complications, such as
heart disease, blindness, and kidney failure."
BIOSAFE Medical Technologies, Inc. is a world leader in the development
of micro blood sample testing technology. Located in Chicago, Illinois,
BIOSAFE Laboratories, Inc. is a subsidiary of BIOSAFE Medical Technologies,
Inc., and develops, manufactures, and processes health monitoring and
screening products for the consumer, physician, health screening,
occupational health, pharmaceutical, disease-management, and medical
research markets.
Glycemion, Inc. is an independent distributor of the BIOSAFE Disease
Risk Assessment and other rapid results products and marketing services.
BIOSAFE Medical Technologies, Inc.
http://www.ebiosafe.com
Glycemion, Inc de pe piaþã BIOSAFE prima FDA Aprobat de consum Diabetul de evaluare a riscurilor, disponibilã în Statele Unite - Glycemion, Inc. To Market BIOSAFE's First FDA Approved Consumer Diabetes Risk Assessment Available In The United States - articole medicale engleza - startsanatate